Key facts
- Notable investors include US National Science Foundation, U.S. Department of Energy, TEDCO, University of Maryland, Orbia Ventures — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Silvec
- ·The full record, as it builds
Funding rounds
No funding rounds for Silvec are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Silvec
Developer of RNA therapies designed to inoculate trees, vines, and bushes against diseases, eliminating the need for genetic modification. The company's RNA therapy involves introducing a virus-like RNA bacterium into the tree veins to destroy viral and fungal pathogens, enabling food growers to ensure abundant, diverse food supplies while protecting natural resources.
- Sector
- Healthcare
- HQ
- Gaithersburg, MD, United States
- Founded
- 2019
- Employees
- 14
- Website
- silvec.com/
- Ownership
- Privately Held (backing)
Silvec doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Silvec shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Silvec in its N-PORT filings yet. We sweep new filings monthly.